Top

Breast Cancer

Published in:

01-01-2022 | Metastasis | Original Article

FE65 in breast cancer and its clinicopathological significance

Authors: Junyao Xu, Erina Iwabuchi, Yasuhiro Miki, Ayako Kanai, Takanori Ishida, Hironobu Sasano

Published in: Breast Cancer | Issue 1/2022

Abstract

Background

Transcription coregulator adapter protein FE65 is well known to play pivotal roles in pathogenesis of Alzheimer’s disease by regulating amyloid precursor protein (APP) expression and processing. APP was recently reported to be also involved in development of human malignancies. Therefore, in this study, we studied FE65 status in different subtypes of human breast cancer and correlated the results with cell proliferation and migration of carcinoma cells and clinicopathological features of breast cancer patients to explore its biological and clinical significance in breast cancer.

Methods

We first immunolocalized FE65 and APP in 138 breast cancer patients and correlated the results with their tumor grade. Then, we did further exploration by proximity ligation assay, WST-8, and wound-healing assay.

Results

FE65 immunoreactivity in carcinoma cells was significantly associated with lymph-node metastasis, ERα, and high pathological N factor. APP immunoreactivity was significantly positively correlated with high pathological N factor. FE65, APP, and p-APP were all significantly correlated with shorter disease-free survival of breast cancer patients. In addition, the status of FE65 was significantly associated with overall survival. Results of in vitro analysis revealed that FE65 promoted the migration and proliferation of T-47D and ZR-75–1 breast carcinoma cells. In situ proximity ligation assay revealed that FE65 could bind to APP in the cytoplasm. FE65 was also associated with APP and ERα in carcinoma cells, suggesting their cooperativity in promoting carcinoma cell proliferation and migration. APP was also significantly associated with adverse clinical outcome of the patients.

Conclusions

This is the first study to explore the clinical significance of FE65 in human breast cancer. The significant positive correlation of FE65 with poor clinical outcome, direct binding to APP, and promotion of carcinoma cell proliferation and migration indicated that FE65–APP pathway could serve as the potential candidate of therapeutic intervention in breast cancer patients.

Fitzmaurice C, Abate D, Abbasi N, et al. Global burden of disease cancer. JAMA Oncol. 2019. https://doi.org/10.1001/jamaoncol.2019.2996.CrossRefPubMedPubMedCentral

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. https://doi.org/10.3322/caac.21262.CrossRefPubMed

Zambrano N, Buxbaum JD, Minopoli G, et al. Interaction of the phosphotyrosine interaction/phosphotyrosine binding-related domains of Fe65 with wild-type and mutant Alzheimer’s beta-amyloid precursor proteins. J Biol Chem. 1997;272(10):6399–405. https://doi.org/10.1074/jbc.272.10.6399.CrossRefPubMed

Nakaya T, Kawai T, Suzuki T. Regulation of FE65 nuclear translocation and function by amyloid beta-protein precursor in osmotically stressed cells. J Biol Chem. 2008;283(27):19119–31. https://doi.org/10.1074/jbc.M801827200.CrossRefPubMed

LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer’s disease. Nat Rev Neurosci. 2007;8(7):499–509. https://doi.org/10.1038/nrn2168.CrossRefPubMed

Sabo SL, Ikin AF, Buxbaum JD, Greengard P. The Alzheimer amyloid precursor protein (APP) and FE65, an APP-binding protein, regulate cell movement. J Cell Biol. 2001;153(7):1403–14. https://doi.org/10.1083/jcb.153.7.1403.CrossRefPubMedPubMedCentral

Strecker P, Ludewig S, Rust M, et al. FE65 and FE65L1 share common synaptic functions and genetically interact with the APP family in neuromuscular junction formation. Sci Rep. 2016;6:25652. https://doi.org/10.1038/srep25652.CrossRefPubMedPubMedCentral

Hu Q, Hearn MG, Jin LW, et al. Alternatively spliced isoforms of FE65 serve as neuron-specific and non-neuronal markers. J Neurosci Res. 1999;58(5):632–40. https://doi.org/10.1002/(sici)1097-4547(19991201)58:5%3c632::aid-jnr4%3e3.0.co;2-p.CrossRefPubMed

Borquez DA, Gonzalez-Billault C. The amyloid precursor protein intracellular domain-fe65 multiprotein complexes: a challenge to the amyloid hypothesis for Alzheimer’s disease? Int J Alzheimers Dis. 2012;2012: 353145. https://doi.org/10.1155/2012/353145.CrossRefPubMedPubMedCentral

10.

Borg JP, Ooi J, Levy E, Margolis B. The phosphotyrosine interaction domains of X11 and FE65 bind to distinct sites on the YENPTY motif of amyloid precursor protein. Mol Cell Biol. 1996;16(11):6229–41. https://doi.org/10.1128/mcb.16.11.6229.CrossRefPubMedPubMedCentral

11.

McLoughlin DM, Miller CC. The FE65 proteins and Alzheimer’s disease. J Neurosci Res. 2008;86(4):744–54. https://doi.org/10.1002/jnr.21532.CrossRefPubMed

12.

Guenette SY, Chen J, Ferland A, et al. hFE65L influences amyloid precursor protein maturation and secretion. J Neurochem. 1999;73(3):985–93. https://doi.org/10.1046/j.1471-4159.1999.0730985.x.CrossRefPubMed

13.

Sabo SL, Lanier LM, Ikin AF, et al. Regulation of beta-amyloid secretion by FE65, an amyloid protein precursor-binding protein. J Biol Chem. 1999;274(12):7952–7. https://doi.org/10.1074/jbc.274.12.7952.CrossRefPubMed

14.

Pandey P, Sliker B, Peters HL, et al. Amyloid precursor protein and amyloid precursor like protein 2 in cancer. Oncotarget. 2016. https://doi.org/10.18632/oncotarget.7103.CrossRefPubMedPubMedCentral

15.

Tsang JYS, Lee MA, Ni YB, et al. Amyloid precursor protein is associated with aggressive behavior in nonluminal breast cancers. Oncologist. 2018;23(11):1273–81. https://doi.org/10.1634/theoncologist.2018-0012.CrossRefPubMedPubMedCentral

16.

Takagi K, Ito S, Miyazaki T, et al. Amyloid precursor protein in human breast cancer: an androgen-induced gene associated with cell proliferation. Cancer Sci. 2013;104(11):1532–8. https://doi.org/10.1111/cas.12239.CrossRefPubMedPubMedCentral

17.

Ito S, Miki Y, Saito R, et al. Amyloid precursor protein and its phosphorylated form in non-small cell lung carcinoma. Pathol Res Pract. 2019;215(8): 152463. https://doi.org/10.1016/j.prp.2019.152463.CrossRefPubMed

18.

Sun Y, Sun J, Lungchukiet P, et al. Fe65 suppresses breast cancer cell migration and invasion through Tip60 mediated cortactin acetylation. Sci Rep. 2015;5:11529. https://doi.org/10.1038/srep11529.CrossRefPubMedPubMedCentral

19.

Minopoli G, Gargiulo A, Parisi S, et al. Fe65 matters: new light on an old molecule. IUBMB Life. 2012;64(12):936–42. https://doi.org/10.1002/iub.1094.CrossRefPubMed

20.

Sun Y, Kasiappan R, Tang J, et al. A novel function of the Fe65 neuronal adaptor in estrogen receptor action in breast cancer cells. J Biol Chem. 2014;289(18):12217–31. https://doi.org/10.1074/jbc.M113.526194.CrossRefPubMedPubMedCentral

21.

Strilic B, Yang L, Albarran-Juarez J, et al. Tumour-cell-induced endothelial cell necroptosis via death receptor 6 promotes metastasis. Nature. 2016;536(7615):215–8. https://doi.org/10.1038/nature19076.CrossRefPubMed

22.

Jiang L, Yu G, Meng W, et al. Overexpression of amyloid precursor protein in acute myeloid leukemia enhances extramedullary infiltration by MMP-2. Tumour Biol. 2013;34(2):629–36. https://doi.org/10.1007/s13277-012-0589-7.CrossRefPubMed

23.

Tsang JYS, Lee MA, Chan TH, et al. Proteolytic cleavage of amyloid precursor protein by ADAM10 mediates proliferation and migration in breast cancer. EBioMedicine. 2018;38:89–99. https://doi.org/10.1016/j.ebiom.2018.11.012.CrossRefPubMedPubMedCentral

24.

Shi C, Zhu X, Wang J, et al. Estrogen receptor alpha promotes non-amyloidogenic processing of platelet amyloid precursor protein via the MAPK/ERK pathway. J Steroid Biochem Mol Biol. 2014. https://doi.org/10.1016/j.jsbmb.2014.06.010.CrossRefPubMed

25.

Wu X, Chen S, Lu C. Amyloid precursor protein promotes the migration and invasion of breast cancer cells by regulating the MAPK signaling pathway. Int J Mol Med. 2020;45(1):162–74. https://doi.org/10.3892/ijmm.2019.4404.CrossRefPubMed

26.

Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–90. https://doi.org/10.1016/j.cell.2009.11.007.CrossRef

Title: FE65 in breast cancer and its clinicopathological significance
Authors: Junyao Xu
Erina Iwabuchi
Yasuhiro Miki
Ayako Kanai
Takanori Ishida
Hironobu Sasano
Publication date: 01-01-2022
Publisher: Springer Singapore
Keywords: Metastasis
Breast Cancer
Breast Cancer
Published in: Breast Cancer / Issue 1/2022
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-021-01291-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Impact of serum vitamin D on the response and prognosis in breast cancer patients treated with neoadjuvant chemotherapy

Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study

LncRNA SNHG5 promotes the glycolysis and proliferation of breast cancer cell through regulating BACH1 via targeting miR-299

Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer

Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer

Breast cancer patient-reported outcome of factors influencing cosmetic satisfaction after breast-conserving therapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer